Chou2 Pharma and Ethos Discovery Partner to Advance Cannabinoid Therapy for Canine Epilepsy
Key Insights
Chou2 Pharma (search) and Ethos Discovery (search) are collaborating on a study to assess a novel cannabinoid formulation for treating idiopathic epilepsy (search) in dogs.
The study will evaluate the pharmacokinetics of Chou2 Pharma (search)'s proprietary drug, with plans for a subsequent proof-of-concept efficacy study.
Current treatments for canine epilepsy (search) are often ineffective or cause significant side effects, highlighting the need for improved therapies.
Chou2 Pharma (search) LLC has partnered with Ethos Discovery (search) to study a potential new therapy for canine idiopathic epilepsy (search), a condition affecting many dogs and often proving difficult to manage. The collaboration aims to evaluate the pharmacokinetics of Chou2 Pharma’s proprietary drug, a precision cannabinoid formulation, with a subsequent proof-of-concept efficacy study planned.
Unmet Needs in Canine Epilepsy Treatment
Idiopathic epilepsy (search) presents a significant challenge in veterinary medicine, as 30-40% of affected dogs show resistance to available treatments, resulting in frequent or severe seizures. Existing treatment options often involve a combination of drugs, which can lead to severe side effects, potentially diminishing the quality of life for these animals. Dr. Khanna from Ethos Discovery (search) emphasized the need for improved treatments, stating, "This is a therapeutic area of veterinary medicine that would greatly benefit from an improved drug that is more consistently effective and comes with a stronger safety profile."
Chou2 Pharma's Cannabinoid Platform
The experimental therapy is built on Chou2 Pharma (search)’s precision cannabinoid formulating platform. Brian Segebrecht, CEO of Chou2 Pharma, expressed enthusiasm about the partnership, stating, "Partnering with an organization like Ethos Discovery (search) in the early stages of developing this new potential companion animal drug is critical to our ultimate goal of utilizing our unique platform for treating more pets with therapeutic needs that are underserved."
Study Design and Objectives
The study will commence early this year and focus on evaluating the pharmacokinetics of the cannabinoid formulation. Following this, a proof-of-concept efficacy study will be conducted in dogs diagnosed with epilepsy (search). The primary objective is to assess the drug's safety and efficacy in reducing the frequency and severity of seizures, while also minimizing side effects.
Vision for Veterinary Medicine
John Payne, Co-founder and Executive Chairman of Chou2 Pharma (search), noted, "It's rewarding to see our vision coming to life in such an important therapeutic area. Ethos Discovery (search) is a highly respected research organization, and we look forward to working with them on this study, and more studies in the future as we expand upon the full therapeutic potential of cannabinoid molecules in veterinary medicine."
The outcomes of this study could pave the way for innovative treatments, offering hope to dog owners and veterinarians alike in managing epilepsy (search) while improving the well-being of pets. The partnership represents a promising step forward in veterinary pharmaceuticals, addressing a critical unmet need in canine health.